Evidence map›Paper›PMID 34153344›Full record

ReviewNeuroscience and biobehavioral reviews2021

Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.

Fabiola De Marchi, Ivana Munitic, Amedeo Amedei, James D Berry, Eva L Feldman, Eleonora Aronica, Giovanni Nardo, Donatienne Van Weehaeghe, Elena Niccolai, Nikolina Prtenjaca and 3 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuroscience and biobehavioral reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Cell type-specific gene therapy confers protection against motor neuron disease caused by a TFG variant.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 5 countries.

Fabiola De MarchiDepartment of Neurology and ALS Centre, University of Piemonte Orientale, Maggiore Della Carità Hospital, Corso Mazzini 18, Novara, 28100, Italy.
Ivana MuniticLaboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, R. Matejcic 2, 51000, Rijeka, Croatia.
Amedeo AmedeiDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
James D BerrySean M. Healey & AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, 165 Cambridge Street, Suite 600, Boston, MA, 02114, USA.
Eva L FeldmanDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Eleonora AronicaAmsterdam UMC, University of Amsterdam, Department of (Neuro) Pathology, Amsterdam Neuroscience, Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
Giovanni NardoLaboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milanm, 20156, Italy.
Donatienne Van WeehaegheDivision of Nuclear Medicine, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Elena NiccolaiDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Nikolina PrtenjacaLaboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, R. Matejcic 2, 51000, Rijeka, Croatia.
Stacey A SakowskiDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Caterina BendottiLaboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milanm, 20156, Italy.
Letizia MazziniDepartment of Neurology and ALS Centre, University of Piemonte Orientale, Maggiore Della Carità Hospital, Corso Mazzini 18, Novara, 28100, Italy. Electronic address: letizia.mazzini@uniupo.it.
Mario Negri Institute for Pharmacological Research · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Florence · ITUniversity of Michigan · USUniversity of Rijeka · HRAmsterdam Neuroscience · NLKU Leuven · BEMassachusetts General Hospital · US

Funding

Mapping the ALS Exposome to Gain New Insights into Disease Risk and PathogenesisR01ES030049 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BATTERMAN, STUART A, FELDMAN, EVA LUCILLE · 2020 to 2024
$3.5M
Metabolomic Signatures Linking ALS to Persistent Organic Pollutant ExposuresR01TS000289 · TS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FELDMAN, EVA LUCILLE · 2018 to 2020
$1.5M
ATSDR CDC HHS R01 TS000289NIEHS NIH HHS R01 ES030049
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a debilitating and rapidly fatal neurodegenerative disease. Despite decades of research and many new insights into disease biology over the 150 years since the disease was first described, causative pathogenic mechanisms in ALS remain poorly understood, especially in sporadic cases. Our understanding of the role of the immune system in ALS pathophysiology, however, is rapidly expanding. The aim of this manuscript is to summarize the recent advances regarding the immune system involvement in ALS, with particular attention to clinical translation. We focus on the potential pathophysiologic mechanism of the immune system in ALS, discussing local and systemic factors (blood, cerebrospinal fluid, and microbiota) that influence ALS onset and progression in animal models and people. We also explore the potential of Positron Emission Tomography to detect neuroinflammation in vivo, and discuss ongoing clinical trials of therapies targeting the immune system. With validation in human patients, new evidence in this emerging field will serve to identify novel therapeutic targets and provide realistic hope for personalized treatment strategies.

Indexed as

Amyotrophic Lateral SclerosisNeurodegenerative DiseasesAnimalsHumansImmune SystemPositron-Emission TomographyAmyotrophic lateral sclerosisBiomarkersImmunityInflammationTargetTargeted therapies

Identifiers

PMID34153344
PMCPMC8428677
OpenAlexW3176697917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.